OR WAIT null SECS
The company will expand its production facilities in Carlow and Cork to meet increased global demand for its medicines and vaccines produced in Ireland.
MSD, known as Merck in the US and Canada, announced on May 30, 2017 that it will invest EUR280 million at two of its manufacturing sites in Ireland over the next three years. The company says 330 new jobs will be created, which include technical, engineering, biochemistry, biology, quality, and operations positions. The expansion of MSD’s Carlow and Cork facilities and production capacity is in response to the increased global demand for MSD’s medicines and vaccines produced in Ireland. The company’s headquarters and manufacturing division will remain in the US.
The facility in Brinny, Co. Cork is an integrated site for the development, testing, and manufacturing of biologics. It specializes in the fermentation, purification, and sterile filling of biotech products. More than 200 new jobs will be created to meet the demand for MSD’s medicines for lung cancer, melanoma, hepatitis C, and rheumatoid arthritis.
The Carlow manufacturing site is the company’s first stand-alone vaccine and biologics facility outside the US. MSD plans to create 120 new roles here. Carlow also is an important link in MSD’s network of sites producing new immuno-oncology treatment for the global market.
MSD currently employs more than 1600 people across four sites in Ireland-Carlow, Cork, Dublin, and Tipperary. The company’s Irish operations encompasses manufacturing, commercial, global financial services, and marketing facilities. It reported a turnover of EUR4.7 billion in 2016.
MSD’s legacy in Ireland stretches back over the past 50 years. The company invest more than $2.5 billion in expanding and developing its Irish facilities. MSD provides healthcare solutions and innovative medicines in areas such as diabetes, heart disease, immuno-oncology, infectious diseases, and vaccines.